Olmesartan medoxomil for the treatment of hypertension in children and adolescents
Giuliano Tocci1, Massimo Volpe1,21Chair and Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine, University of Rome “Sapienza”, Sant’Andrea Hospital, Rome; 2IRCCS Neuromed, Pozzilli, ItalyAbstract: Prevalence of hypertension in chi...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2011-03-01
|
Series: | Vascular Health and Risk Management |
Subjects: | |
Online Access: | https://www.dovepress.com/olmesartan-medoxomil-for-the-treatment-of-hypertension-in-children-and-peer-reviewed-article-VHRM |
id |
doaj-973b66a79e794dd189fb21df2c969931 |
---|---|
record_format |
Article |
spelling |
doaj-973b66a79e794dd189fb21df2c9699312020-11-24T22:39:56ZengDove Medical PressVascular Health and Risk Management1178-20482011-03-01Volume 71771816897Olmesartan medoxomil for the treatment of hypertension in children and adolescentsVolpe MTocci GGiuliano Tocci1, Massimo Volpe1,21Chair and Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine, University of Rome “Sapienza”, Sant’Andrea Hospital, Rome; 2IRCCS Neuromed, Pozzilli, ItalyAbstract: Prevalence of hypertension in children and adolescents has progressively and continuously increased over recent decades. Thus, early and effective control of high blood pressure may be considered an effective therapeutic approach, in order to reduce the burden of hypertension-related cardiovascular disease in future. In the past, due to the absence of prospective, long-term, randomized, controlled clinical trials performed in young hypertensive patients, lifestyle changes have been long seen as the only strategy to reduce high blood pressure levels. More recently, clinical data on the efficacy and safety of five major classes of antihypertensive drugs (including angiotensin converting enzyme inhibitors, angiotensin receptor blockers [ARBs], beta-blockers, calcium-antagonists, and diuretics) have become available. In particular, these trials demonstrated dose-dependent blood pressure reductions and a good tolerability profile of several ARBs in hypertensive children and adolescents. An overview is provided of the clinical benefits of early detection and prompt intervention of high blood pressure levels, with a closer analysis of recent clinical trials, performed with olmesartan medoxomil in young subjects with hypertension.Keywords: hypertension, high blood pressure, children, adolescents, antihypertensive treatment, olmesartan medoxomilhttps://www.dovepress.com/olmesartan-medoxomil-for-the-treatment-of-hypertension-in-children-and-peer-reviewed-article-VHRMhypertensionhigh blood pressurechildrenadolescentsantihypertensive treatmentolmesartan medoxomil. |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Volpe M Tocci G |
spellingShingle |
Volpe M Tocci G Olmesartan medoxomil for the treatment of hypertension in children and adolescents Vascular Health and Risk Management hypertension high blood pressure children adolescents antihypertensive treatment olmesartan medoxomil. |
author_facet |
Volpe M Tocci G |
author_sort |
Volpe M |
title |
Olmesartan medoxomil for the treatment of hypertension in children and adolescents |
title_short |
Olmesartan medoxomil for the treatment of hypertension in children and adolescents |
title_full |
Olmesartan medoxomil for the treatment of hypertension in children and adolescents |
title_fullStr |
Olmesartan medoxomil for the treatment of hypertension in children and adolescents |
title_full_unstemmed |
Olmesartan medoxomil for the treatment of hypertension in children and adolescents |
title_sort |
olmesartan medoxomil for the treatment of hypertension in children and adolescents |
publisher |
Dove Medical Press |
series |
Vascular Health and Risk Management |
issn |
1178-2048 |
publishDate |
2011-03-01 |
description |
Giuliano Tocci1, Massimo Volpe1,21Chair and Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine, University of Rome “Sapienza”, Sant’Andrea Hospital, Rome; 2IRCCS Neuromed, Pozzilli, ItalyAbstract: Prevalence of hypertension in children and adolescents has progressively and continuously increased over recent decades. Thus, early and effective control of high blood pressure may be considered an effective therapeutic approach, in order to reduce the burden of hypertension-related cardiovascular disease in future. In the past, due to the absence of prospective, long-term, randomized, controlled clinical trials performed in young hypertensive patients, lifestyle changes have been long seen as the only strategy to reduce high blood pressure levels. More recently, clinical data on the efficacy and safety of five major classes of antihypertensive drugs (including angiotensin converting enzyme inhibitors, angiotensin receptor blockers [ARBs], beta-blockers, calcium-antagonists, and diuretics) have become available. In particular, these trials demonstrated dose-dependent blood pressure reductions and a good tolerability profile of several ARBs in hypertensive children and adolescents. An overview is provided of the clinical benefits of early detection and prompt intervention of high blood pressure levels, with a closer analysis of recent clinical trials, performed with olmesartan medoxomil in young subjects with hypertension.Keywords: hypertension, high blood pressure, children, adolescents, antihypertensive treatment, olmesartan medoxomil |
topic |
hypertension high blood pressure children adolescents antihypertensive treatment olmesartan medoxomil. |
url |
https://www.dovepress.com/olmesartan-medoxomil-for-the-treatment-of-hypertension-in-children-and-peer-reviewed-article-VHRM |
work_keys_str_mv |
AT volpem olmesartanmedoxomilforthetreatmentofhypertensioninchildrenandadolescents AT toccig olmesartanmedoxomilforthetreatmentofhypertensioninchildrenandadolescents |
_version_ |
1725706822905495552 |